Home » Topics » Immuno-oncology, BioWorld Science

Immuno-oncology, BioWorld Science
RSS

Follow-up data presented for Bexxar cancer therapy

June 15, 1999

Theragyn improves long-term survival in ovarian cancer patients

June 14, 1999

Data from phase I/II study of NBI-3001 presented at German Society of Neurosurgery

June 11, 1999

Dendreon moves ahead with dendritic cell therapies for cancer

June 10, 1999

Maxamine plus IL-2 prolongs duration of complete remission in patients with AML

June 10, 1999

European Commission issues first approval for tasonermin

June 8, 1999

LifeTime and Dovetail enter exclusive agreement for Beta LT anticancer compound

June 8, 1999

AVI BioPharma to initiate phase II clinical trial of Avicine in pancreatic cancer

June 7, 1999

Additional phase II data suggest modifications for AVI BioPharma's cancer vaccine

June 1, 1999

Phase II trial of York Medical's cancer vaccine cleared

June 1, 1999

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 2, 2026.
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
AND-017 increases RBC and hemoglobin in sickle cell disease
BioWorld Science
Sickle cell disease (SCD) is an inherited hemoglobinopathy caused by a mutation in the gene encoding β-globin that results in hemoglobin S polymerization, red...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...